Ιωάννη Κρανιδιώτη 2

555 35, Πυλαία, Θεσσαλονίκη

+30 2310 475 662

Καθημερινές : 9:00 - 14:00

info@hcds.gr

https://hcds.gr/epikoinonia/

In Severe COVID-19, No Benefit Seen with Lopinavir–Ritonavir

Treatment with lopinavir–ritonavir did not add value beyond standard care in severely ill patients hospitalized with novel coronavirus disease (COVID-19). Findings from the open-label, randomized trial appear in the New England Journal of Medicine.

Roughly 200 adults in China hospitalized with COVID-19 and oxygen saturation of 94% or lower were assigned to lopinavir–ritonavir twice daily for 14 days plus standard care, or standard care alone. The primary outcome — time to clinical improvement — did not differ between the groups (median, 16 days). Mortality at 28 days was numerically lower with lopinavir–ritonavir, but the between-groups difference did not reach statistical significance (19% with lopinavir–ritonavir, 25% with standard care alone).


original article: jwatch

Σχολιάστε

Αυτός ο ιστότοπος χρησιμοποιεί το Akismet για να μειώσει τα ανεπιθύμητα σχόλια. Μάθετε πώς υφίστανται επεξεργασία τα δεδομένα των σχολίων σας.

στοιχεία σύνδεσης

Kατηγορίες

Recent Posts

Ιστορικό

κοινοποιήστε στο :

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on skype
Skype
Share on email
Email